USA - NASDAQ:OCGN - US67577C1053 - Common Stock
The current stock price of OCGN is 1.17 USD. In the past month the price increased by 12.5%. In the past year, price increased by 5.41%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 20.42 | 382.04B | ||
AMGN | AMGEN INC | 12.52 | 147.02B | ||
GILD | GILEAD SCIENCES INC | 14.32 | 137.56B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 23.1 | 100.34B | ||
REGN | REGENERON PHARMACEUTICALS | 12.6 | 60.95B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 60.46B | ||
ARGX | ARGENX SE - ADR | 81.16 | 46.04B | ||
ONC | BEONE MEDICINES LTD-ADR | 5.72 | 38.90B | ||
INSM | INSMED INC | N/A | 30.60B | ||
NTRA | NATERA INC | N/A | 24.02B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.86B | ||
BIIB | BIOGEN INC | 8.97 | 21.06B |
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. The company is headquartered in Malvern, Pennsylvania and currently employs 95 full-time employees. The company went IPO on 2014-12-03. Its technology pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. The company is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Leber congenital amaurosis, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. The company is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
OCUGEN INC
11 Great Valley Parkway
Malvern PENNSYLVANIA 19355 US
CEO: Shankar Musunuri
Employees: 95
Phone: 14843284701
The current stock price of OCGN is 1.17 USD. The price decreased by -2.5% in the last trading session.
The exchange symbol of OCUGEN INC is OCGN and it is listed on the Nasdaq exchange.
OCGN stock is listed on the Nasdaq exchange.
10 analysts have analysed OCGN and the average price target is 6.63 USD. This implies a price increase of 466.67% is expected in the next year compared to the current price of 1.17. Check the OCUGEN INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
OCUGEN INC (OCGN) has a market capitalization of 365.39M USD. This makes OCGN a Small Cap stock.
OCUGEN INC (OCGN) currently has 95 employees.
OCUGEN INC (OCGN) has a support level at 1.05 and a resistance level at 1.2. Check the full technical report for a detailed analysis of OCGN support and resistance levels.
The Revenue of OCUGEN INC (OCGN) is expected to decline by -3.28% in the next year. Check the estimates tab for more information on the OCGN EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
OCGN does not pay a dividend.
OCUGEN INC (OCGN) will report earnings on 2025-11-06.
OCUGEN INC (OCGN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.2).
The outstanding short interest for OCUGEN INC (OCGN) is 17.73% of its float. Check the ownership tab for more information on the OCGN short interest.
ChartMill assigns a technical rating of 8 / 10 to OCGN. When comparing the yearly performance of all stocks, OCGN turns out to be only a medium performer in the overall market: it outperformed 57.76% of all stocks.
ChartMill assigns a fundamental rating of 1 / 10 to OCGN. Both the profitability and financial health of OCGN have multiple concerns.
Over the last trailing twelve months OCGN reported a non-GAAP Earnings per Share(EPS) of -0.2. The EPS decreased by -11.11% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -106.24% | ||
ROE | -1865.63% | ||
Debt/Equity | 9.18 |
10 analysts have analysed OCGN and the average price target is 6.63 USD. This implies a price increase of 466.67% is expected in the next year compared to the current price of 1.17.
For the next year, analysts expect an EPS growth of -21.69% and a revenue growth -3.28% for OCGN